CEFODIZIME (THR-221) IN RESPIRATORY TRACT INFECTIONS

概要

論文の詳細を見る
Cefodizime, a new cephem antibiotic, was applied to the treatment of twenty patients with respiratory tract infections. The drug was administered by i.v. drip infusion, mainly at 2 g/day, divided into two doses, for 4-14 days. The results were: excellent in 9 cases, good in 6, ineffective in 3 and unknown in 1, and not evaluable in 1 (mycoplasma pneumonia). The 3 ineffective cases were far advanced bronchiectasis with symptomatic aggravation caused by P. aeruginosa 1, obstructive pneumonia with lung cancer 1, and 1 very old patient with pneumonia. No pathogenic agents were isolated in the last 2 cases. Another case was excluded because of ARDS complicating pulmonary tuberculosis on day 4 of treatment. Stomatitis was observed in one case, but was thought to have no correlation with this drug. Serum GOT, GPT and for Al- P elevated slightly during chemotherapy in 3 cases, whose pretreatment values were already elevated. These recovered soon after cessation of chemotherapy. We consider this drug useful for treating respiratory tract infections, except for infections due to P. aetuginosa.
公益社団法人日本化学療法学会の論文